Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
0.916
-0.005 (-0.59%)
At close: Dec 20, 2024, 4:00 PM
0.958
+0.042 (4.64%)
After-hours: Dec 20, 2024, 6:36 PM EST
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Seres Therapeutics stock have an average target of 5.63, with a low estimate of 1.25 and a high estimate of 10. The average target predicts an increase of 514.96% from the current stock price of 0.92.
Analyst Consensus: Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for MCRB stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 5 | 4 | 4 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +992.30% | Nov 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $1.25 | Strong Buy | Maintains | $1.25 | +36.54% | Nov 13, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 24, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +992.30% | Sep 13, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +992.30% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
n/a
from 126.33M
Revenue Next Year
40.49M
EPS This Year
-0.11
from -0.89
EPS Next Year
-0.51
from -0.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 131.3M | 78.8M | ||
| Avg | n/a | 40.5M | 19.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 94.5% | ||
| Avg | - | - | -51.4% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.09 | -0.02 | -0.20 | |
| Avg | -0.11 | -0.51 | -0.52 | |
| Low | -0.12 | -0.72 | -0.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.